CD8A and neoplasm: In summary, the above results indicate that BF10 outperforms subcomponent treatments in the active immune signature of tumor samples and that BF10 increases TCR clonotype diversity in CD8+ cells from tumors and tdLNs to the greatest extent compared with subcomponents or control.